18F-FDG PET/CT影像组学预测乳腺癌患者新辅助化疗病理完全缓解
该回顾性研究纳入100例接受新辅助化疗的乳腺癌患者,从治疗前PET/CT提取2210个影像组学特征,用机器学习筛选预测病理完全缓解的影像组学因子。影像组学预测模型在训练集准确率0.857(AUC=0.844),独立验证集准确率0.767(AUC=0.722);加入年龄后训练集AUC升至0.958、验证集AUC为0.73,均优于临床预测模型。作者认为治疗前PET/CT影像组学联合年龄可预测病理完全缓解。
要点
- 治疗前PET/CT影像组学特征联合患者年龄可预测乳腺癌新辅助化疗后的病理完全缓解。
- 影像组学特征与受体表达及肿瘤T分期存在密切关联。
- 联合年龄的模型在训练集AUC为0.958、独立验证集AUC为0.73,均优于临床预测模型。
核心结论
- 治疗前PET/CT影像组学预测因子联合患者年龄能够预测乳腺癌新辅助化疗后的病理完全缓解,作者认为这些数据对患者管理有价值。
研究设计与样本
- 回顾性研究纳入100例接受新辅助化疗的乳腺癌患者,从PET/CT提取2210个影像组学特征,采用无监督与有监督机器学习模型筛选预测因子,以随机森林构建预测模型,并经10折交叉验证重复30次及独立验证评估性能。
主要发现
- PET/CT影像组学预测因子在训练集准确率为0.857(AUC=0.844),在独立验证集准确率为0.767(AUC=0.722)。
- 加入年龄后,训练集准确率为0.857(AUC=0.958),独立验证集准确率为0.8(AUC=0.73),两者均优于临床预测模型。
- 影像组学特征与受体表达及肿瘤T分期之间存在密切关联。
关键数值与推荐
- 影像组学特征筛选采用共识聚类和Wilcoxon符号秩检验选取显著特征(p<0.05),经单变量随机森林和Pearson相关矩阵选取最具判别力特征,再基于多变量随机森林的遍历特征选择确定最具预测力特征。
- 模型性能以曲线下面积(AUC)、敏感度、特异度、阳性预测值(PPV)和阴性预测值(NPV)衡量。
临床怎么用
- 作者认为治疗前PET/CT影像组学联合年龄预测病理完全缓解的数据对患者管理有价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is commonly accepted as the gold standard to assess outcome after NAC in breast cancer patients. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) has unique value in tumor staging, predicting prognosis, and evaluating treatment response. Our aim was to determine if we could identify radiomic predictors from PET/CT in breast cancer patient therapeutic efficacy prior to NAC. METHODS: This retrospective study included 100 breast cancer patients who received NAC; there were 2210 PET/CT radiomic features extracted. Unsupervised and supervised machine learning models were used to identify the prognostic radiomic predictors through the following: (1) selection of the significant (p < 0.05) imaging features from consensus clustering and the Wilcoxon signed-rank test; (2) selection of the most discriminative features via univariate random forest (Uni-RF) and the Pearson correlation matrix (PCM); and (3) determination of the most predictive features from a traversal feature selection (TFS) based on a multivariate random forest (RF). The prediction model was constructed with RF and then validated with 10-fold cross-validation for 30 times and then independently validated. The performance of the radiomic predictors was measured in terms of area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: The PET/CT radiomic predictors achieved a prediction accuracy of 0.857 (AUC = 0.844) on the training split set and 0.767 (AUC = 0.722) on the independent validation set. When age was incorporated, the accuracy for the split set increased to 0.857 (AUC = 0.958) and 0.8 (AUC = 0.73) for the independent validation set and both outperformed the clinical prediction model. We also found a close association between the radiomic features, receptor expression, and tumor T stage. CONCLUSION: Radiomic predictors from pre-treatment PET/CT scans when combined with patient age were able to predict pCR after NAC. We suggest that these data will be valuable for patient management.
引用
- Li P, Wang X, Xu C, et al. 18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 31982990. doi:10.1007/s00259-020-04684-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。